| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 196.05 | 21.0% |
| Total Income | 196.64 | 21.2% |
| Expenditure | 172.27 | 22.1% |
| PBT | 24.37 | 14.6% |
| Net Profit | 20.49 | 0.9% |
| OPM | 20.08% | 3.64pp |
| NPM | 10.42% | 2.28pp |
| EPS | 2.31 | 3.8% |
SMS Pharmaceuticals Reports 24% YoY Increase in PAT for Q1 FY26
10 Aug 2025 · 10 Aug 2025, 10:01 pm
Summary
SMS Pharmaceuticals Ltd has reported a 24% Year-over-Year (YoY) increase in Profit After Tax (PAT) for the first quarter of the financial year 2026. The company's revenue grew by 19% YoY, driven by strong demand for key APIs. The EBITDA margin remained stable at 20%, improving 364 bps sequentially but down 30 bps YoY. The company has successfully commissioned its backward integration project and expects a meaningful improvement in margins over the next few quarters.
Key Highlights
- 1
Revenue up 19% YoY on higher volumes
- 2
EBITDA up 17% YoY (EBITDA margin: 20%)
- 3
PAT margin steady at 10%
- 4
Backward integration for key APIs commissioned in June 2025
- 5
R&D investment to double over 18 months to accelerate pipeline development
- 6
250 crore Capex plan on track
Management Comments
Mr. P. Vamsi Krishna
Executive Director
We commenced FY26 on a strong footing, driven by our diversified product portfolio and notable client wins in key APIs. We made strong progress on our strategic roadmap, laying a solid foundation for the next five years of growth. Our joint venture with Chemo continues to be value accretive, with our anti-diabetic portfolio gaining market share in Europe. We are also deepening our strategic partnership with them through an expanded basket of anti-diabetic products. In Ibuprofen, we continue to see growing demand, supported by strong visibility in regulated markets and a competitive cost position driven by improved processes and plant engineering.
Informational and educational content only. Not investment advice.